Ottaiano, A., Capozzi, M., Tafuto, S., De Stefano, A., De Divitiis, C., Romano, C., . . . Nasti, G. (2019). Folfiri-Aflibercept vs. Folfiri-Bevacizumab as Second Line Treatment of RAS Mutated Metastatic Colorectal Cancer in Real Practice. Front Oncol.
Citação norma ChicagoOttaiano, Alessandro, Monica Capozzi, Salvatore Tafuto, Alfonso De Stefano, Chiara De Divitiis, Carmela Romano, Antonio Avallone, and Guglielmo Nasti. "Folfiri-Aflibercept Vs. Folfiri-Bevacizumab As Second Line Treatment of RAS Mutated Metastatic Colorectal Cancer in Real Practice." Front Oncol 2019.
Citação norma MLAOttaiano, Alessandro, et al. "Folfiri-Aflibercept Vs. Folfiri-Bevacizumab As Second Line Treatment of RAS Mutated Metastatic Colorectal Cancer in Real Practice." Front Oncol 2019.